-- Ipsenâ€™s Tanakan Sales May Fall 35% This Year, CEO Tells Investir
-- B y   T a r a   P a t e l
-- 2012-02-04T11:40:58Z
-- http://www.bloomberg.com/news/2012-02-04/ipsen-s-tanakan-sales-may-fall-35-this-year-ceo-tells-investir.html
Ipsen SA (IPN)  Chief Executive Officer Marc de Garidel said the loss of reimbursement by the French health
system for the drug Tanakan would lower sales of the memory-loss
medicine by about 35 percent this year,  Investir  reported,
citing an interview.  Ipsen is in talks with more than one company for a
partnership for its French primary-care unit as well as a buyer
for its manufacturing site in Dreux,  France , he was cited as
saying.  To contact the reporter on this story:
Tara Patel in Paris at 
 tpatel2@bloomberg.net   To contact the editor responsible for this story:
Dick Schumacher at 
 dschumacher@bloomberg.net  